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Abstract
Background: Interaction of aristololactam-b-D-glucoside and daunomycin with tRNA
phe was investigated using various
biophysical techniques.
Methodology/Principal Findings: Absorption and fluorescence studies revealed that both the compounds bind tRNA
phe
non-cooperatively. The binding of daunomycin was about one order of magnitude higher than that of aristololactam-b-D-
glucoside. Stronger binding of the former was also inferred from fluorescence quenching data, quantum efficiency values
and circular dichroic results. Results from isothermal titration calorimetry experiments suggested that the binding of both
compounds was predominantly entropy driven with a smaller but favorable enthalpy term that increased with
temperature. A large favorable electrostatic contribution to the binding of daunomycin to tRNA
phe was revealed from salt
dependence data and the dissection of the free energy values. The electrostatic component to the free energy change for
aristololactam-b-D-glucoside-tRNA
phe interaction was smaller than that of daunomycin. This was also inferred from the
slope of log K versus [Na
+] plots. Both compounds enhanced the thermal stability of tRNA
phe. The small heat capacity
changes of -47 and -99 cal/mol K, respectively, observed for aristololactam-b-D-glucoside and daunomycin, and the
observed enthalpy-entropy compensation phenomenon confirmed the involvement of multiple weak noncovalent
interactions. Molecular aspects of the interaction have been revealed.
Conclusions/Significance: This study presents the structural and eneregetic aspects of the binding of aristololactam-b-D-
glucoside and daunomycin to tRNA
phe.
Citation: Das A, Bhadra K, Suresh Kumar G (2011) Targeting RNA by Small Molecules: Comparative Structural and Thermodynamic Aspects of Aristololactam-b-D-
glucoside and Daunomycin Binding to tRNA
phe. PLoS ONE 6(8): e23186. doi:10.1371/journal.pone.0023186
Editor: Vladimir N. Uversky, University of South Florida College of Medicine, United States of America
Received May 27, 2011; Accepted July 11, 2011; Published August 16, 2011
Copyright:  2011 Das et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Network Project NWP0036 of CSIR, Government of India, CSIR Senior Research Fellowship (to AD) and CSIR
Research Associateship (to KB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gskumar@csiriicb.in
¤ Current address: Department of Zoology, Kalyani University, Kalyani, West Bengal, India
Introduction
The biological macromolecule RNA has attracted recent
attention for its key role in various steps of gene expression. The
recent knowledge of the essential role of cellular RNAs in several
critical life processes and in the progression of many diseases,
particularly viral infections like HIV, AIDS, and hepatitis C, has
led to a growing interest in the molecule as a potential target for
therapeutic intervention [1–3]. This has been augmented by the
recent discovery of a number of micro RNAs and unraveling of
their various functions [4,5]. Consequently, a paradigm shift of
interest from DNA binding molecules to RNA binding molecules
has occurred recently, focusing intense research for the design and
development of new RNA targeted therapeutic agents [6–9]. A
rational design of RNA targeted small molecule therapeutics
essentially requires both detailed knowledge of the structural
details of RNAs and the molecular nature of the interaction
phenomena. RNA binding studies have been severely hampered
due to the lack of high-resolution conformational information and
the complex RNA structures. However, recent advancements in
structural aspects of RNAs through X-ray, NMR and computa-
tional studies have enabled detailed studies on the elucidation of
the mode and mechanism of interaction of many new RNA
binding molecules [10,11]. For example, the aminoglycosides are a
group of extensively studied RNA binding drugs that interact with
the functional sites on 16 s of rRNA [12–14]. Although
aminoglycoside antibiotics target key RNA molecules of bacteria
and viruses, their therapeutic use is severely limited due to high
toxicity [15]. We have been studying the interaction of a group of
natural alkaloids with RNA targets like tRNA and poly(A) [16–
19]. It was revealed that natural isoquinoline alkaloids constitute a
group of molecules that may be useful in selectively targeting RNA
through various means [20–23] Needless to say, RNA molecules
have highly versatile structures that can fold into a multitude of
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23186conformations, and these complex structural motifs may be
potential binding pockets for specific drug recognition sites that
need to be understood in details.
Aristololactam-b-D-glucoside (ADG, Fig. 1A) is an alkaloid of
the Aristolochia group that have attracted recent attention for their
anti tumoral activites [24,25]. The alkaloid has close resemblance
to the clinically used anticancer agent daunomycin (DAU, Fig. 1B)
as both have planar structuresl carrying sugar moieties, and bind
to double stranded DNA by intercalation exhibiting guanine-
cytosine base pair specificity [26–28]. The clinical importance and
biotarget of ADG is still not established although many studies
have revealed its potential biological utility [24,29]. For such an
effective DNA binder with close structural similarity to daunomy-
cin, it is of great importance to obtain detailed information on the
binding characteristics to RNA and this prompted us to undertake
a comparative interaction study of this alkaloid and DAU with
tRNA
Phe (tRNA hereafter) (Fig. 1C) from a variety of biophysical
studies. tRNA represents one of the most common and most
thoroughly characterized natural RNAs. They are versatile
molecules with unique cloverleaf structures exhibiting high degree
of folding, their structures being stabilized by base pairing and
other tertiary interactions. They constitute about 15% of the total
cellular RNA and bind to the A-site of ribosomes. Recently there
has been an increasing interest in understanding the binding of
many small molecules to tRNA [30–33].
Results and Discussion
Spectrophotometric studies and elucidation of binding
affinity
In the visible absorption spectral region (300–600 nm) both
ADG and DAU have characteristic peaks that could be monitored
to understand the binding of these molecules to tRNA. The
changes in the absorption spectra may be conveniently used to
monitor the interaction. In Fig. 2A–B absorption spectral changes
in ADG and DAU on titration with increasing concentration of
tRNA are presented. The spectrum marked ‘1’ is the absorption
spectra of free drug molecules in each case. All the absorption
spectral titrations showed hypochromic and bathochromic effects.
Titration of tRNA with ADG (Fig. 2A) showed hypochromic
change at 398 nm gradually with increasing P/D (nucleotide
phosphate/ligand molar ratio) and a slight bathochromic shift of
4–5 nm with an isosbestic point at 417 nm. At saturating P/D, the
change in hypochromicity was about 23%. On the other hand,
DAU-tRNA showed larger hypochromic effect at 480 nm with
increasing P/D, with a red shift of about 16 nm and hypochro-
micity change of about 31% at saturation (Fig. 2B). The results of
the spectrophotometric titration data were expressed as Scatchard
plots that were analyzed further by the McGhee-von Hippel
methodology [34] for non cooperative binding for evaluation of
the binding constants The Scatchard plots are depicted in the inset
of Fig. 2. From this analysis, it was found that the binding affinity
values (K9) of ADG and DAU to tRNA were 4.33610
4 M
21 and
2.12610
5 M
21, respectively. The number of binding sites was
around two and one, respectively, for ADG and DAU. These
values are presented in Table 1. The binding affinity of DAU to
tRNA is higher and of the order of 10
5 M
21 while the binding
affinity of ADG was smaller compared to DAU.
Fluorescence spectral titration and quenching studies
ADG and DAU are strongly florescent molecules. Their
emission spectra are in the 400–600 and 500–700 nms regions,
respectively, with maximum around 483 and 556 nm when
excited around 400 and 480 nms. Complexation was monitored
by titration studies keeping a constant concentration of the drug
and increasing the concentration of tRNA. A progressive
quenching of the fluorescence was observed for both ADG and
DAU, eventually reaching the saturation point without any shift in
the wavelength maximum (Fig. 3A–B). But the extent of
quenching was significantly different in each case. Maximum
fluorescence quenching (67%) was observed in DAU-tRNA system
(Fig. 3B) indicating a strong association of the DAU molecules to
the tRNA whereas quenching of ADG fluorescence (Fig. 3A) was
comparatively lower, at about 43%. Thus, the fluorescence
titration studies indicated that a stronger quenching was observed
for the DAU system. Analysis of the data through Scatchard and
McGhee-von Hippel methodology gave binding affinity values
(Table 1) close to that obtained from spectroscopy results. This
trend in the binding affinity values was similar to that obtained
from absorption spectral studies.
The Stern-Volmer quenching constant (Ksv) of the fluorescence
of ADG and DAU by tRNA calculated from the fluorescence
spectra revealed values of (1.1560.12)610
4 and (3.9060.12)6
10
4 M
21, respectively. The quenching constants also indicate the
strong bimolecular binding process between the drugs and tRNA
over other unimolecular photophysical processes. This study
underscores the significant affinity of both compounds to tRNA
and the higher affinity of DAU over ADG.
The fluorescence quenching method is a reliable method for
studying the binding mode of small molecules to nucleic acids is.
Molecules bound to the surface of the polyanionic macromolecule
Figure 1. Chemical structures. (A) aristololactam–b-D-glucoside and (B) daunomycin and (C) the cloverleaf structure of yeast tRNA
phe.
doi:10.1371/journal.pone.0023186.g001
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helix will be protected from the quencher [35,36]. An anionic
quencher like [Fe(CN)6]
42 cannot access the inside of the helix
due to the electrostatic barrier from the negatively charged
phosphate groups and consequently very little quenching will be
observed in case of small molecules bound in the interior of the
tRNA helix. Consequently, the magnitude of the Stern-Volmer
quenching constant (Ksv) of ligands that are bound inside will be
lower than that of the free molecules. In Fig. 4, the data on the
fluorescence quenching of ADG-tRNA and DAU-tRNA com-
plexes in presence of K4[Fe(CN)6 is presented. Ksv values of free
ADG and DAU with [Fe(CN)6]
42 were 59.0 and 84.3 M
21,
respectively, while that of bound ones were 41.0 and 44.2 M
21,
respectively, for ADG and DAU indicating that the bound ADG
and DAU molecules are considerably protected and sequestered
away from the solvent. This result suggests an intercalative or
similar kind of binding inside the tRNA helix. The binding of
daunomycin to tRNA was previously investigated by Shafer by
thermal melting and fluorescence studies and intercalation was
suggested [37]. The present data further reveals a more efficient
binding of DAU compared to ADG.
Determination of quantum efficiency
The quantum efficiency (Q) of a nucleic acid binding ligand is a
measure of the energy transferred from the nucleic acid to the
ligand upon complexation and is evaluated from the ratio of the
quantum efficiency of ligand complexed to nucleic acid (qb) to the
quantum efficiency of the free ligand (qf). Determination of
quantum efficiency [38] further supports the strong binding of
ADG and an even stronger binding of DAU to tRNA. A plot of
DAbsorbance against the inverse of tRNA concentration gave an
exponential plot (not shown) from which quantum efficiency
values of 0.68 and 0.46, respectively, have been determined for
ADG and DAU. It can be observed that Q is ,1.0 and this
denotes that both ADG and DAU exhibit greater fluorescence
when free in solution compared to the bound state, i.e. the loss of
fluorescence energy is more efficient when bound to the tRNA
helix. This observation suggests that the loss of fluorescence energy
through interactions with the solvent could occur more efficiently
from the free ligand than the bound ligand.
Binding stoichiometry (Job plot)
The binding stoichiometry of association of ADG and DAU
with tRNA and the possible number of binding sites were
determined independently by continuous variation analysis (Job
plot) [39] in fluorescence. In Job plot, the ligand: RNA molar ratio
is varied while the total molar concentration remains constant.
The stoichiometry of binding is determined by the molar ratio
where maximal binding is observed. The plot of difference
fluorescence intensity (DF) at 483 and 556 nms, respectively for
ADG and DAU, versus their mole fractions presented in Fig. 5,
revealed a single binding mode for both these molecules on the
tRNA. From the inflection points x=0.315 and 0.471 (indicated
by arrow), the number of nucleotides bound per ADG and DAU
can be estimated to be around 2.17 and 1.12, respectively. This is
in good agreement with the number of binding sites obtained from
the non-cooperative McGhee-von Hippel analysis of the spectro-
photometric data (Table 1).
Circular dichroic spectral studies
The conformational changes on tRNA associated with the
binding of ADG and DAU were probed through circular dichroic
(CD) studies. The CD spectrum of tRNA was characterized by a
large positive band around 270 nm (curve 1, Fig. 6A–B) that is
typical of an A-form RNA conformation. There was a moderate
decrease in the ellipticity of this positive band as the binding
progressed, indicating most likely a disruption of the base stacking
interactions, and the extent of change was larger in DAU
compared to ADG. To see whether the binding induced any
optical activity in the bound drug molecules, a study of induced
Figure 2. Absorption spectral titration of drugs with tRNA. (A) ADG (11 mM) treated with 0, 55, 110, 165, 220, 330, 440, 550 and 660 mM
(curves 1–9) of tRNA and (B) DAU (10.4 mM) treated with 0, 20.8, 52, 83.2, 124.8, 166.4, 208, 312 and 364 mM (curves 1–9) of tRNA. Inset: representative
Scatchard plot of each complexation. The solid lines represent the non-linear least square best fit of the experimental points to the neighbour
exclusion model.
doi:10.1371/journal.pone.0023186.g002
Table 1. Binding parameters of tRNA complexation with ADG
and DAU obtained from spectrophotometric and
spectrofluorimetric studies in CP buffer 20 mM [Na
+]a t2 0 uC.
Drug Spectrophotometry Spectrofluorimetry
K9/10
4 M
21 n K9/10
4 M
21 n
ADG 4.3360.20 2.1360.30 6.3860.20 2.2560.05
DAU 21.2060.30 1.2060.20 18.5860.32 1.3160.10
All the data presented are average of four determinations.
doi:10.1371/journal.pone.0023186.t001
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a constant concentration of the drugs and varying the concentra-
tion of tRNA. Induced CD indicates the CD of the ligand in its
absorption region where the RNA does not have any contribution
and is generated due to the asymmetric arrangement of the bound
molecules on the helix. The result of such study is presented in the
insets of Fig. 6A and B. The induced CD spectrum with increasing
tRNA, denoted as curve 1 was characterized by a minimum at
310 nm. The ellipticity of this band decreased as the P/D
decreased. This study indicated the strong chiral environment of
the bound molecules in the stranded organization of tRNA and is
due to the effective coupling of the transition moments of the
bound drug with the transition moments of the chirally arranged
base/base pairs. It may be noted that ADG has no CD in the 200–
4000 nm region while DAU has a weak intrinsic CD in the region
that enhanced in ellipticity on binding to tRNA.
Figure 3. Fluorescence spectral titration of drugs and tRNA. (A) ADG (3.07 mM) treated with 0, 15.35, 30.7, 46.05, 61.4, 92.1, 122.8, 168.85 and
214.9 mM (curves 1–8) of tRNA and (B) DAU (3.0 mM) treated with 0, 15, 30, 45, 60, 75, 90, 105 and 120 mM (curves 1–8) of tRNA.
doi:10.1371/journal.pone.0023186.g003
Figure 4. Stern-Volmer plots for the quenching of the
fluorescence of drugs-tRNA complex by K4[Fe(CN)6]. (A) ADG
and (B) DAU. Symbols are in absence (#) ADG, (%) DAU and, in presence (N)
ADG and (&) DAU of tRNA.
doi:10.1371/journal.pone.0023186.g004
Figure 5. Job’s plot for the binding of ADG and DAU with tRNA.
(A) ADG and (B) DAU.
doi:10.1371/journal.pone.0023186.g005
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Isothermal titration calorimetry (ITC) is an effective tool to
thermodynamically characterize the binding of small molecules to
macromolecules [40,41]. ITC essentially provides insight into the
energetics of the complexation along with quantitative values of
the binding affinity and stoichiometry of the reaction. Because
ITC measures heat exchange it provides a tool independent of the
spectroscopic changes that occur in the reaction. Therefore, this
technique was used to characterize the thermodynamic profiles of
tRNA-ADG and tRNA-DAU complex formation. The top panel
of Fig. 7 presents the representative primary data from the
calorimetric titration of tRNA into solutions of ADG and DAU at
20uC. Each heat burst curve in the figure corresponds to a single
injection. These injection heats were corrected by subtracting the
corresponding dilution heats derived from the injection of identical
amounts of tRNA into the buffer alone (upper panels, curves off set
for clarity). In Fig. 7 (bottom panel) the resulting corrected heats
are plotted against the molar ratio. The data points in this panel
reflect the experimental points and the continuous line represents
the calculated best fit to the data. It can be seen that the binding
was characterized by exothermic heats. The ITC data were fit to a
single site model as the integrated heat data showed only one
binding event. The result yielded a binding affinity (K) value of
(6.5060.04)610
4 M
21, a free energy change (DG)o f26.44 kcal/
mol, an enthalpy change (DH)o f21.02 kcal/mol, an entropy
contribution (TDS) of 5.42 kcal/mol and a binding site size of 2.10
nucleotides for ADG and a K of (2.2260.05)610
5 M
21, DGo f
27.14 kcal/mol, DH of 21.42 kcal/mol and entropy of
25.72 kcal/mol for DAU (Table 2). The overall binding affinities
observed from ITC and the K9 values from spectroscopic binding
are comparable and the trend is the same. Energetics of the
interaction indicates that the binding was favored by small
negative enthalpy and large positive entropy changes in both the
cases. The large positive entropy term is suggestive of the
disruption and release of water molecules on intercalation of
ADG and DAU with sugar moieties into the RNA helix. There are
many examples in the literature for entropy driving nonspecific
small molecule–DNA and RNA interactions that essentially
involve the release of solvent and counterions from the interface
[42,43]. Specific examples are actinomycin and netropsin
interaction with DNA, quinacrine and sanguinarine interactions
with poly(A) etc. [42,43]. However, it may be noted that previous
reports on the thermodynamic profile of daunomycin-DNA
interaction suggested an enthalpically driven binding and not
entropy favoured one [42,44,45]. It s likely that the structural
difference between tRNA and DNA may be responsible for this
difference in the energetics of the interaction.
Dependence of binding on the ionic strength
Previously published data from our laboratory suggested that
electrostatic interactions are not so important for tRNA binding of
isoquinoline alkaloids [20]. On the contrary, the binding of
aminoglycosides to RNA have been reported to be driven by
strong electrostatic interactions [46,47]. We studied the effect of
salt concentration on the binding of ADG and DAU to tRNA in
conjunction with van’t Hoff analysis through calorimetric
experiments. As the [Na
+] concentration was increased from
10 mM to 50 mM [Na
+], the binding affinity of the interaction
decreased from 9.9610
4 M
21 to 4.2610
4 for ADG and from
3.85610
5 M
21 to 8.4610
4 M
21 for DAU (Table 2). Thus the
binding of both ADG and DAU are thermodynamically linked to
Na+ concentration. Polyelectrolytic theories based on Manning’s
counter ions condensation model describe the process and provide
a basis for interpreting this data [48]. From polyelectrolytic theory,
the slope of the best fit line for a plot of log K versus log [Na+]i s
related to the counterion release [42]
SK~dlog(K)=dlog Naz ½  ðÞ ~{Zy ð1Þ
where SK is equivalent to the number of couterions released upon
binding of a drug, Z is the apparent charge of the bound ligand
per phosphate binding and y is the fraction of [Na
+] bound per
phosphate group. The slope of the plot of log K versus log [Na
+]
(Fig. S1) gave values of 20.53 and 20.93, respectively, for ADG
and DAU. The values of Zy reported for daunomycin-DNA
complexes are in the range 0.84–1.08 [44,49]. These values
represent the counter ions released per phosphate upon binding
and suggest stronger electrostatic contact of DAU over ADG with
tRNA. This has been further verified by partitioning the
electrostatic (DGpe) and nonelectrostatic (DGt) contributions to
the Gibbs energy (Fig. S2). The polyelectrolytic contribution to the
overall observed free energy can be quantitatively estimated from
the relationship
DGpe~Zy RTln Naz ½  ðÞ ð 2Þ
Figure 6. Circular dichroic spectra of tRNA-drug complexes. tRNA (60 mM) treated with (A) 30, 60, 90 and 108 mM (curves 1–4) of ADG and (B)
18, 36, 60 and 90 mM of DAU. Inset: Induced circular dichroic spectra of ADG and DAU, respectively.
doi:10.1371/journal.pone.0023186.g006
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can be calculated as the difference between DG and DGpe. Here
Zy is the slope of the van’t Hoff plot. At 50 mM [Na
+], the
contribution of DGpe have been determined to be 1.63 kcal/mol
and 0.93 kcal/mol, respectively, for DAU and ADG. These are
about 25 and 15%, respectively, of the total free energy change.
The positively charged DAU exhibits high level of electrostatic
contribution compared to ADG. In case of ADG, it has been
suggested that a weak transient positive charge may be developed
at the N6 position in presence of nucleic acids [50,51]. It is likely
that such transient charge development is the cause of the
observed weak but significant electrostatic contribution to the
binding. Clearly the electrostatic contributions to the binding of
both DAU and ADG to tRNA are much lower than the
contributions from the non electrostatic forces.
Heat capacity change of binding
Temperature dependence of the binding enthalpy measurement
allows the determination of the change in heat capacity (DCp) using
the equation DCp=d(DH)/dT. Heat capacity provides a link
between the structural and energetic data and may describe
hydration-dehydrationeffectsthatoccurduringthebindingprocess.
Temperature dependence ITC was performed in the range 10 to
25uC and the thermodynamic parameters are elucidated at each
temperature. These data are presented in Table 3. The association
constant varied from (1.1860.08)610
5 M
21 at 10uC to (2.90
60.2)610
4 M
21 at 25uC for ADG and from (3.0060.07)610
5 at
10uC to (1.2660.03)610
5 M
21 at 25uC for DAU. Essentially, the
binding affinity decreased by about four times over the temperature
range for ADG and about three times for DAU. The binding
enthalpy values increased and the favorable entropy contribution
Figure 7. ITC profiles for the binding of (A) ADG and (B) DAU with tRNA. The top panels represent the raw data for sequential injection of
tRNA into drug solution and the bottom panels show the integrated heat data after correction of heat of dilution against molar ratio of poly(A)/drug.
The data points (closed circle) were fitted to a one site model, and the solid lines represent the best fit data.
doi:10.1371/journal.pone.0023186.g007
Table 2. ITC derived thermodynamic profiles for the binding of ADG and DAU to tRNA at different Na+ concentrations in CP buffer
at 20uC.
Drug NaCl (mM) K/10
4 M
21 N DG/kcal mol
21 DH/kcal mol
21 TDS/kcal mol
21 DGt/kcal mol
21 DGpe/kcal mol
21 ZY
10 9.960.5 2.0460.02 26.7460.05 21.3560.01 5.4060.01 5.3160.01 1.4360.02
ADG 20 6.560.3 2.1060.02 26.5060.04 21.0260.01 5.4260.01 5.2860.02 1.2160.03 20.5360.04
50 4.260.1 2.4060.03 26.2460.02 20.5860.02 5.6260.02 5.3160.02 0.9360.03
10 38.560.3 1.0960.02 27.5460.02 21.7160.02 5.7160.01 5.0360.01 2.5160.02
DAU 20 22.260.1 1.1560.05 27.2160.03 21.4260.02 5.7260.02 5.0860.02 2.1360.01 20.9360.01
50 8.4060.2 1.3660.02 26.6460.03 20.4860.02 6.1260.03 5.0160.01 1.6360.01
The data in this table are derived from ITC experiments conducted in CP buffer. K and DH values were determined from fits of the ITC profiles, with indicated errors
reflecting standard deviations of the experimental data from the fitted curves. The value of DG were determined using the equation DG=2(RTlnK). The values of TDS
were determined using equation TDS=DH-DG. The uncertainties in the determinations are indicated. The ITC profiles were fit with a model for single binding site.
doi:10.1371/journal.pone.0023186.t002
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changes occurred in the free energy values. The reaction enthalpy
and entropy, both of which were strong functions of temperature,
compensate to make the reaction free energy more or less
independent of temperature (Fig. 8). Such compensation was
observed for many biomolecular interactions [52–54] and suggests
the involvement of significant hydrophobic interactions in the
binding. The temperature dependence of the enthalpy change was
used to estimate change in heat capacity (DCp). The slope of the line
revealed a value of 247 and 299, respectively, for ADG and DAU
(Table 3). Negative heat capacity values have been observed for a
variety of small molecules binding to DNA [42,54–58] and RNA
[19,52]. Change in solvent accessible surface area (SASA) has been
shown tobeamajorcomponentofDCp [59–61].Further,structured
water like the water of hydrophobic hydration can be associated
with large heat capacity and the release of such water on transfer of
the non-polar groups into the interior of the helix can contribute a
negative term to the DCp. Murphy and Churchill have discussed
four types or modes of DNA recognition by small molecules, which
are sequence specific, nonspecific, minimal sequence specific and
structure specific [55]. Small negative DCp values have been
implicated to be associated with a minimal sequence specific
binding reactions. The slightly negative non-zero DCp value that is
observed for ADG and DAU-tRNA complexation appears to
denote structure specific binding. It is known that for DNA
intercalators and groove binders a large hydrophobic contribution
to the binding free energy is expected from their aromatic ring
system and bindingshould be energeticallyfavorable [62]. From the
Records relationship, DGhyd=80(610)6DCp, the free energy
contribution from the hydrophobic transfer step of binding of these
molecules may be calculated [62]. The DGhyd values for ADG and
DAU binding to tRNA were deduced to be 23.8 and 27.9 kcal/
mol, respectively, well within the range observed for intercalating
molecules [58,59].
Thermal melting studies
The ability of ADG and DAU to enhance the stability of tRNA
on complexation was investigated from optical melting and
differential scanning calorimetry studies. The native tRNA exhibits
an optical melting profile (Fig. 9A) with three transitions that has
been stabilized by the presence of bound molecules. The DSC
thermogramsoftRNA canbedeconvolutedtothreetransitionswith
Tm values of 38, 50 and 61uC, respectively (Fig. 9B). These are in
agreement with the previous reports [20,63,64]. The transitions
were reversible but the non unity value for the ratio of the
calorimetric (DHcal) and van’t Hoff (DHvan’t Hoff) enthalpy indicated
that the melting of the tRNA may not be obeying a simple two state
transition process. The melting of transition I was not affected on
binding of ADG and DAU. ADG stabilizes the second transition by
about 2uC while a higher stabilization of about 4uC was effected by
DAU. A larger stabilization of 7uC by ADG and 12.5uC by DAU
was effected on the third transition (Fig. 9 C,D). This result further
reiterates the strong binding of DAU to tRNA compared to ADG.
Conclusions
Interaction of the sugar containing molecules aristololactam-b-
D-glucoside and daunomycin with tRNA
phe was investigated.
Scatchard plots from absorption and fluorescence titrations
revealed that both the compounds bind to tRNA non coopera-
tively. Fluorescence quenching studies suggested both ADG and
DAU are bound inside the helical organization of the tRNA, most
likely by intercalation, but the former is bound more tightly. A
large favorable component for electrostatic contribution to the
binding of ADG and DAU to tRNA was revealed from the salt
dependent data and the dissection of the free energy term that
correlated with the entropic contribution. The binding of ADG
and DAU to tRNA was predominantly entropy driven with a
smaller favorable enthalpy term that enhanced with temperature.
The small but negative heat capacity change of 247 and 299 cal/
Table 3. ITC derived thermodynamic profiles for the binding of ADG and DAU to tRNA at different temperatures in CP buffer
20 mM [Na
+].
Drug
T
(K) K/10
5 M
21 N
DG
kcal mol
21
DH
kcal mol
21
TDS
kcal mol
21 DCp/cal mol K
283 1.1860.01 2.0560.01 26.6060.01 20.6360.01 5.9760.02
ADG 293 0.6560.03 2.1060.02 26.4460.03 21.0260.01 5.4260.02 24762
298 0.2960.02 2.5460.05 26.0660.03 21.3560.02 4.7160.03
283 3.0060.01 1.0860.01 27.1060.01 20.7360.01 6.3760.02
DAU 293 2.2260.01 1.1560.01 27.1460.02 21.4260.02 5.7260.01 29963
298 1.2660.02 1.2160.02 26.8560.04 22.2960.05 4.5660.02
All the data in this table are derived from ITC experiments. K and DH values were determined from fits of the ITC profiles, with indicated errors reflecting standard
deviations of the experimental data from the fitted curves. The value of DG were determined using the equation DG=2(RTlnK). The values of TDS were determined
using equation TDS=DH-DG. The uncertainties in the determinations are indicated. The ITC profiles were fit with a model for single binding site.
doi:10.1371/journal.pone.0023186.t003
Figure 8. Plot of variation of thermodynamic parameters. DG (#,
%)a n dDH (N, &) verses TDS for the binding of ADG and DAU to tRNA.
doi:10.1371/journal.pone.0023186.g008
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phenomenon observed confirmed the involvement of multiple
weak noncovalent interactions in the binding process. Both the
drugs enhanced the thermal stability of tRNA. Circular dichroism
studies provided evidence for a small but significant perturbation
of the tRNA structure. Taken together, the results suggest that the
binding of these molecules on the tRNA
phe structure appears to be
mostly by partial intercalation, but with significant contribution
from electrostatic forces. Many well-known molecules like
aminoglycosides bind RNA with strong electrostatic interactions
[46,47]. Since molecular recognition of RNA by small molecules is
an area of immense current interest, our present results may
contribute to the development of better small molecule based
RNA therapeutic agents.
Materials and Methods
Biochemicals
tRNA
Phe (yeast) and daunomycin were purchased from Sigma-
Aldrich Corporation (St. Louis, MO, USA). The ratio of the
absorbance at 260 to 280 nm was around 1.85 for tRNA
indicating that the sample was free from protein contaminations.
Aristololactam- b-D-glucoside was extracted in our laboratory
from Aristolochia indica and crystallized from ethanol [65,66].
Preparation of stock solutions
tRNA solution was prepared in the experimental buffer and
dialyzed in cold room. Its concentration was determined
spectrophotometrically using a molar extinction coefficient (e)o f
6900 (M
21 cm
21) at 260 nm expressed in terms of nucleotide
phosphates [20,64]. Stock solutions of ADG and DAU were
prepared in the experimental buffer and kept protected in the dark
till use. The concentrations of ADG and DAU were determined by
absorbance measurement using molar extinction coefficients as
follows: ADG-10,930 M
21 cm
21 at 398 nm (in dimethyl sulfox-
ide) and DAU-11,500 M
21 cm
21 at 480 (in aqueous buffer),
respectively [50,51]. No deviation from Beer’s law occurred in the
concentration range employed in this study. All experiments were
conducted in Citrate-Phosphate (CP) buffer (10 mM [Na
+]),
pH 7.0, containing 0.5 mM Na2HPO4. The pH was adjusted
using citric acid. For ADG binding studies the buffer contained
additionally 240 mM of DMSO [50]. Glass distilled deionized
water and analytical grade reagents were used throughout. pH
measurements were made on a Sartorius high precision pH meter
with a semi micro electrode (Sartorius AG, Germany) with an
accuracy of .60.01 units. All buffer solutions were filtered
through 0.45 mm Millipore filters (Millipore, India Pvt. Ltd,
Bangalore, India) before use.
Absorbance and fluorescence spectroscopy
Electronic absorption spectral titrations were performed on a
Shimadzu Pharmaspec 1700 spectrophotometer (Shimadzu Cor-
poration, Tokyo, Japan) at 2060.5uC using the methodology of
Chaires et al [67] and described previously in details by us [20,68].
Briefly, a known concentration of the RNA solution was kept in
the sample and reference cuvettes and small aliquots of a known
concentration of the drug was titrated into the sample cuvette.
After each addition, the solution was thoroughly mixed and
Figure 9. Optical and DSC melting profiles of tRNA-drug complexes. (A) optical melting of tRNA alone (m), in presence of ADG (N) and in
presence of DAU (&), (B) DSC thermograms of tRNA, (C) tRNA-ADG complex and (D) tRNA-DAU complex.
doi:10.1371/journal.pone.0023186.g009
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wavelength maximum and the isosbestic point. The data obtained
from these titrations were utilized for constructing Scatchard plots.
Steady state fluorescence measurements were performed on a
Hitachi F4010 fluorescence spectrometer (Hitachi Ltd., Tokyo,
Japan) or Shimadzu RFPC 5301 spectrofluorimeter in fluores-
cence free quartz cuvettes of 1 cm path length as described
previously [69]. The excitation wavelengths for ADG and DAU
were 350 nm and 424 nm, respectively. All measurements were
performed keeping excitation and emission band passes of 5 nm.
The sample temperature was maintained at 2061.0uC using Eyela
Uni Cool U55 water bath (Tokyo Rikakikai Co. Ltd., Japan).
Binding affinity calculations
The amounts of free and RNA bound drug were determined as
follows. In absorbance, after each addition of the drug to the
tRNA solution (40 mM), the absorbance data at the respective
isosbestic points were noted and the total drug concentration
present was calculated as Ct=A iso/eiso. This data was then used to
calculate the expected absorbance at wavelength maximum as
Aexp=C telmax. The difference in Aexp and the observed
absorbance (Aobsd) was then used to calculate the amount of
bound drug as Cb=DA/De=(A exp2Aobsd)/(ef2eb). The free drug
concentration was determined by difference, Cf=C t2Cb. The
extinction coefficient of the completely bound drug was deter-
mined by adding a known quantity of the drug to a large excess of
tRNA and on the assumption of total binding, eb=A max/Ct.
Alternatively, the absorbance of a known quantity of drug was
monitored at the wavelength maximum while adding known
amounts of RNA until no further change in absorbance was
observed. Both these protocols gave values within experimental
errors. In fluorescence, the amount of bound drug was calculated
from the relation Cb=C t(I2Io)/(Vo21)Io, where Ct is the known
total drug concentration, I is the observed fluorescence, Io is the
fluorescence intensity of identical concentration of drug in absence
of RNA and Vo is the experimentally determined ratio of the
fluorescence intensity of totally bound drug to that of free drug.
Free drug concentrations (Cf) were obtained from the relationship
Ct=C b+Cf. The binding ratio (r) is defined as r=Cb/[RNA]total.
Binding data obtained from spectrophotometric and spectro-
fluorimetric titrations were converted to Scatchard plots of r/Cf
versus r. The Scatchard plots showed negative slopes at low r values
as observed for noncooperative binding isotherms. Hence the plots
were analyzed using the noncooperative McGhee-von Hippel
equation [34]
r=Cf~K0 1{nr ðÞ 1{nr ðÞ =f1{ n{1 ðÞ rg ½ 
(n{1) ð1Þ
where K9 is the intrinsic binding constant to an isolated binding site
and n is number of nucleotides excluded by the binding of a single
drug molecule. The binding data were analyzed using the Origin
7.0 software (Microcal, Inc., Northampton, MA, USA) that
determines the best-fit parameters to equation (1).
Binding stoichiometry determination
Job’s continuous variation method [39] was employed to
determine the binding stoichiometry in each case using fluores-
cence spectroscopy. At constant temperature, the fluorescence
signal was recorded for solutions where the concentrations of both
RNA and drugs were varied while the sum of their concentrations
was kept constant. The difference in fluorescence intensity (DF) of
the drugs in the absence and presence of RNA was plotted as a
function of the input mole fraction of each drug as reported
previously [43]. The break point in the resulting plot corresponds
to the mole fraction of the bound drug in the complex. The
stoichiometry was obtained in terms of RNA-alkaloid [(1-xalkaloid)/
xalkaloid] where xalkaloid denotes the mole fraction of the respective
alkaloid. The results reported are averages of at least three
experiments.
Fluorescence quenching and quantum efficiency
measurements
Fluorescence quenching studies were carried out with the
anionic quencher [Fe(CN)6J
42. The quenching experiments were
performed by mixing, in different ratios, two solutions, one
containing KCl and the other K4[Fe(CN)6], in addition to the
normal buffer components at fixed total ionic strength. Fluores-
cence quenching experiments were performed at a constant P/D
(RNA base nucleotide/alkaloid molar ratio), monitoring fluores-
cence intensity changes as a function of changing concentration of
ferrocyanide as described previously [19]. At least four measure-
ments were taken for each set and averaged out. The data were
plotted as Stern-Volmer plots of Io/I versus [Fe(CN)6]
42.
Fluorescence quantum efficiency was calculated using the
following equation [35]
Q~qb=qf~Ib=If|ef=eb ð2Þ
where ef and eb represent the molar extinction coefficients of the
free and bound drug and Ib and If are the fluorescence intensities
of bound and free drug respectively. The quantum efficiency was
determined according to the procedure described earlier [19].
Circular dichroism spectroscopy
Circular dichroism (CD) data were taken on a Jasco J815
spectropolarimeter (Japan Spectroscopic Ltd., Japan) at 2060.5uC
as reported earlier [54,68–69]. Temperature control of the spectral
measurements was achieved by a Jasco temperature controller
(model PFD425 L/15). A rectangular quartz cuvette of 1 cm path
length was used. Each spectrum was averaged from five successive
accumulations at a scan rate of 50 nm/min. keeping a bandwidth
of 1.0 nm at a sensitivity of 100 milli degree, and was base line
corrected and smoothed within permissible limits using the inbuilt
software of the unit. The molar ellipticity values [h] are expressed
in terms of either per RNA base nucleotide (210–400 nm) or per
bound alkaloid (300–500 nm). The CD unit was routinely
calibrated using aqueous solutions of d-10 ammonium camphor
sulphonate.
Isothermal titration calorimetry
All isothermal titration calorimetry experiments were performed
using a MicroCal VP-ITC unit (MicroCal Inc., Northampton,
MA, USA) using protocols reported in our previous papers [18–
22,45]. Aliquots of degassed tRNA solution were injected from the
rotating syringe (290 rpm) into the isothermal sample chamber
containing each of the drug solution (1.4235 mL). Corresponding
control experiments to determine the heat of dilution of tRNA
were performed by injecting identical volumes of same concen-
tration of the tRNA into buffer. The duration of each injection was
10 seconds and the delay time between the injections was
240 seconds. The initial delay before the first injection was
60 seconds. Each injection generated a heat burst curve (micro-
calories per second versus time). The area under each heat burst
curve was determined by integration using the Origin 7.0 software
(MicroCal) to give the measure of the heat associated with the
injection. The heat associated with each tRNA-buffer mixing was
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injection to the drug to give the heat of drug binding to the tRNA.
The heat of dilution for injecting the buffer into each of the drug
alone was observed to be negligible. The resulting corrected
injection heats were plotted as a function of the P/D molar ratio,
and fit with a model for one set of binding sites, and analyzed using
Origin 7.0 software to estimate the binding affinity (K), the binding
stoichiometry (N), and the enthalpy of binding (DH). The free
energies (DG) were calculated using the standard relationship
DG~{RT lnK ð3Þ
where R is the gas constant (1.987 cal/K mol) and T is the
temperature in Kelvin (293 K). The binding free energy coupled
with the binding enthalpies derived from the ITC data allowed the
calculation of the entropic contribution to the binding (TDS),
where DS is the calculated binding entropy using the standard
relationship
TDS~DH{DG ð4Þ
Optical melting and differential scanning calorimetry
Absorbance versus temperature profiles (melting curves) of
RNA and RNA-alkaloid complexes were measured on the
Shimadzu Pharmaspec 1700 unit equipped with the peltier
controlled TMSPC-8 model accessory (Shimadzu Corporation,
Tokyo, Japan) as described previously [20,64,70]. In a typical
experiment, the RNA sample (50 mM) was mixed with varying
concentrations of the drug under study in the desired degassed
buffer in to the eight cell micro optical cuvettes of 1 cm path
length. The temperature of the microcell accessory was raised at a
heating rate of 0.5uC/min. while continuously monitoring the
absorbance change at 260 nm. Melting curves allowed an
estimation of melting temperature Tm, the midpoint temperature
of the drug bound RNA unfolding process.
To investigate the helix-coil transition, excess heat capacities
were measured as a function of temperature on a Microcal VP-
differential scanning calorimeter (DSC) (MicroCal Inc., North-
ampton, MA, USA) as described previously [22]. In a series of
DSC scans, both the cells were loaded with the buffer solution,
equilibrated at 20uC for 15 minutes, and scanned from 20u to
100uC at a scan rate of 50uC/hour. The buffer scans were
repeated till reproducible. On cooling, the sample cell was rinsed
and loaded with RNA solution and then with RNA-drug
complexes of different molar ratio. Scanning was done in the
range 20u–100uC. Each experiment was repeated twice with
separate fillings. The DSC thermograms of excess heat capacity
versus temperature were analyzed using the Origin 7.0 software.
The area under the experimental heat capacity (Cp) curve was
used to determine the calorimetric transition enthalpy (DHcal)
given by the equation
DHcal~
ð
Cp dT ð5Þ
where T is the absolute temperature in Kelvin. This calorimet-
rically determined enthalpy is model-independent and is thus
unrelated to the nature of the transition. The temperature at
which excess heat capacity is at a maximum defines the transition
temperature (Tm). The model-dependent van’t Hoff enthalpy
(DHv) was obtained by shape analysis of the calorimetric data and
the cooperativity factor was obtained from the ratio (DHcal/DHv).
To check the reversibility of the transition, the sample was allowed
to cool slowly to 10uC (10uC/h) and a repeat DSC scan was
performed on the renatured sample under identical conditions.
Supporting Information
Figure S1 The slope of the plot of log K versus log [Na
+]
on the binding of ADG (-N-) and DAU (-&-) to tRNA.
(TIF)
Figure S2 Partitioned polyelectrolytic (DGpe) (shaded)
and nonpolyelectrolytic (DGt, black) contributions to the
Gibbs energy of the complexation of ADG (A) and DAU
(B) at different [Na
+] concentrations.
(TIF)
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